智核生物 SmartNuclide | 智核生物 SmartNuclide

OUR MISSION
+ 查看更多

We are dedicated to transforming

the diagnosis and treatment of cancer by

developing innovative, game-changing

radiopharmaceuticals.

SmartNuclide Biopharma Announces First Patient Treated in Phase 1/2 Clinical Trial of SNA001 for Well-Differentiated Thyroid Cancer
2019-02-12
SmartNuclide’s SNA001 Receives NMPA’s First Investigational New Drug Approval for Recombinant Human TSH
2018-10-18
Innovative Radiopharmaceutical Company SmartNuclide Closes Series Pre-A Financing
2018-03-07